Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer

Journal of Clinical Oncology

Volumn 28, Issue 20, 2010, Pages 3219-3226

  Sargent, Daniel J ^a   Marsoni, Silvia ^a   Monges, Genevieve ^a   Thibodeau, Stephen N ^a   Labianca, Roberto ^a   Hamilton, Stanley R ^a   French, Amy J ^a   Kabat, Brian ^a   Foster, Nathan R ^a   Torri, Valter ^a   Ribic, Christine ^a   Grothey, Axel ^a   Moore, Malcolm ^a   Zaniboni, Alberto ^a   Seitz, Jean Francois ^a   Sinicrope, Frank ^a   Gallinger, Steven ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; LEVAMISOLE; MISMATCH REPAIR PROTEIN; ANTINEOPLASTIC ANTIMETABOLITE; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLON CANCER; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TREATMENT FAILURE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MISMATCH REPAIR; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; ADJUVANT CHEMOTHERAPY; COLON TUMOR; DRUG RESISTANCE; FEMALE; GENETICS; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; VALIDATION STUDY;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL MARKERS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DNA MISMATCH REPAIR; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77954748953     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.1825     Document Type: Article

References (48)

1. Moertel CG, Fleming TR, Macdonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352-358, 1990 (Pubitemid 20042739)
2. Wolmark N, Rockette H, Mamounas EP, et al: Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17:3553-3559, 1999 (Pubitemid 29517927)
3. Wolmark N, Rockette H, Fisher B, et al: The benefit of leucovorin-modulated fluorouracil as post-operative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 11:1879-1887, 1993
4. O'Connell MJ, Laurie JA, Kahn M, et al: Prospectively randomized trial of post-operative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16:295-300, 1998 (Pubitemid 28041612)
5. André T, Boni C, Mounedji-Boudiaf L, et al: Oxaliplatin, 5-fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351, 2004 (Pubitemid 38702845)
6. Kuebler JP, Wieand HS, O'Connell MJ, et al: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol 25:2198-2204, 2007 (Pubitemid 46954643)
7. André T, Boni C, Navarro M: Improved overall survival with oxaliplatin, fluorouracil and leucovorin as adjuvant treatment in stage II/III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109-3116, 2009
8. Ionov Y, Peinado MA, Malkhosyan S, et al: Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363:558-561, 1993 (Pubitemid 23186645)
9. Thibodeau SN, Bren G, Schaid D: Microsatellite instability in cancer of the proximal colon. Science 260:816-819, 1993 (Pubitemid 23167612)
10. Lothe RA, Peltomaki P, Meling GI, et al: Genomic instability in colorectal cancer: Relationship to clinicopathological variables and family history. Cancer Res 53:5849-5852, 1993 (Pubitemid 24006146)
11. Kim H, Jen J, Vogelstein B, et al: Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 145:148-156, 1994 (Pubitemid 24217493)
12. Rodríguez-Moranta F, Castells A, Andreu M, et al: Clinical performance of original and revised Bethesda guidelines for the identification of MSH2/ MLH1 gene carriers in patients with newly diagnosed colorectal cancer: Proposal of a new and simpler set of recommendations. Am J Gastroenterol 101:1104-1111, 2006 (Pubitemid 43725327)
13. Piñol V, Castells A, Andreu M, et al: Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 293:1986-1994, 2005
14. Lindor NM, Burgart LJ, Leontovich O, et al: Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 20:1043-1048, 2002 (Pubitemid 34141849)
15. Lanza G, Gafa R, Santini A, et al: Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol 24:2359-2367, 2006 (Pubitemid 46630668)
16. Gryfe R, Kim H, Hsieh ET, et al: Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342:69-77, 2000 (Pubitemid 30036597)
17. Halling KC, French AJ, McDonnell SK, et al: Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 91:1295-1303, 1999 (Pubitemid 29387571)
18. Kakar S, Aksoy S, Burgart LJ, et al: Mucinous carcinoma of the colon: Correlation of loss of mis-match repair enzymes with clinicopathologic features and survival. Mod Pathol 17:696-700, 2004 (Pubitemid 38715493)
19. Popat S, Hubner R, Houlston RS: Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23:609-618, 2005 (Pubitemid 46224239)
20. Ribic CM, Sargent DJ, Moore MJ, et al: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247-257, 2003 (Pubitemid 36859476)
21. Kim GP, Colangelo LH, Wieand HS, et al: Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 25:767-772, 2007 (Pubitemid 350002875)
22. Hemminki A, Mecklin JP, Jarvinen H, et al: Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 119:921-928, 2000
23. Elsaleh H, Joseph D, Grieu F, et al: Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355:1745-1750, 2000 (Pubitemid 30265078)
24. Schrag D, Garewal HS, Burstein HJ, et al: American society of clinical oncology technology assessment: Chemotherapy sensitivity and resistance assays. J Clin Oncol 22:3631-3638, 2004 (Pubitemid 41103670)
25. Peterson B, George SL: Sample size requirements and length of study for testing interaction in a 2 x k factorial design when time-to-failure is the outcome. Control Clin Trials 14:511-522, 1993 (Pubitemid 24003708)
26. O'Connell MJ, Mailliard JA, Kahn MJ, et al: Controlled trial of Fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15:246-250, 1997 (Pubitemid 27020580)
27. IMPACT Investigators: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345:939-944, 1995
28. Laurie JA, Moertel CG, Fleming TR, et al: Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol 7:1447-1456, 1989 (Pubitemid 19245114)
29. Benson AB 3rd, Schrag D, Somerfield MR, et al: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22:3408-3419, 2004 (Pubitemid 41103700)
30. Gill S, Loprinzi CL, Sargent DJ, et al: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? J Clin Oncol 22:1797-1806, 2004 (Pubitemid 41095169)
31. QUASAR Collaborative Group, Gray R, Barnwell J, et al: Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study. Lancet 370:2020-2029, 2007 (Pubitemid 350236339)
32. de Gramont A, Boni C, Navarro J, et al: Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. J Clin Oncol 25:165s, 2007 (suppl, abstr 4007)
33. Roth AD, Tejpar S, Yan P, et al: Correlation of molecular markers in colon cancer with stage-specific prognosis: Results of the translational study on the PETACC3-EORTC 40993-SAKK 60-00 trial. ASCO Gastrointestinal Cancers Symposium, January 15-17, 2009 (abstr 288)
34. Kerr D, Gray R, Quirke P, et al: A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. J Clin Oncol 27:15s, 2009 (suppl; abstr 4000)
35. Jover R, Zapater P, Castells A, et al: Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 55:848-855, 2006 (Pubitemid 43764557)
36. Carethers JM, Smith EJ, Behling CA, et al: Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 126:394-401, 2004 (Pubitemid 38182296)
37. Bertagnolli MM, Niedzwiecki D, Compton CC, et al: Microsatellite instability predicts improves response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and leukemia Group B protocol 89803. J Clin Oncol 27:1814-1821, 2009
38. Zaanan A, Cuilliere-Dartigues P, Parc Y, et al: Impact of microsatellite instability and p53 expression on stage III colon cancer disease-free survival in patients treated by fluorouracil and leucovorin with or without oxaliplatin. J Clin Oncol 26, 2008 (suppl; abstr 15017)
39. Cunningham JM, Kim CY, Christensen ER, et al: The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum Genet 69:780-790, 2001 (Pubitemid 32868523)
40. Cunningham JM, Christensen ER, Tester DJ, et al: Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 58:3455-3460, 1998 (Pubitemid 28371090)
41. Morris M, Platell C, Iacopetta B: Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy. Clin Cancer Res 14:1413-1417, 2008 (Pubitemid 351413923)
42. Carethers JM, Chauhan DP, Fink D, et al: Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 117:123-131, 1999 (Pubitemid 29297628)
43. Arnold CN, Goel A, Boland CR: Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 106:66-73, 2003 (Pubitemid 36750389)
44. Fischer F, Baerenfaller K, Jiricny J: 5-Fluorouracil is efficiently removed from DNAby the base excision and mismatch repair systems. Gastroenterology 133:1858-1868, 2007
45. Jiang Y, Casey G, Lavery IC, et al: Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer. J Mol Diagn 10:346-354, 2008 (Pubitemid 352019121)
46. Wang Y, Jatkoe T, Zhang Y, et al: Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 22:1564-1571, 2004 (Pubitemid 41079793)
47. Johnston PG, Mulligan K, Kay E, et al: A genetic signature of relapse in stage II colorectal cancer derived from formalin fixed paraffin embedded tissue (FFPE) tissue using a unique disease specific colorectal array. J Clin Oncol 24:18S, 2006 (suppl; abstr 3519)
48. Arango D, Laiho P, Kokko A, et al: Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer. Gastroenterology 129:874-884, 2005 (Pubitemid 41242680)